Testing a liver inflammation score in diabetes and fatty liver
Part of Hormones & metabolism clinical trials.
This study tests whether a new scoring method can help doctors identify liver inflammation in patients who have both type 2 diabetes and a fatty liver. The goal is to find an easier, safer way to assess liver health without invasive procedures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with metabolic dysfunction-associated fatty liver disease (MAFLD)—meaning fat has built up in your liver due to metabolic issues
- You have type 2 diabetes mellitus
- You do not have viral hepatitis, drug-induced liver damage, autoimmune liver disease, or alcoholic liver disease
- Your liver has not failed or become severely damaged (no cirrhosis complications)
- You have not had liver surgery or a liver transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new ultrasound device that uses sound waves to measure fat in the liver without needles or surgery. It is for people with a type of fatty liver disease called MASLD or MASH, who are already getting an MRI to check their liver.
This study tests a new blood test to help diagnose fatty liver disease and liver fibrosis. It aims to see how well the test works compared with a liver biopsy. Your participation could help improve diagnosis for others.
This study checks how common a condition called MAFLD is among people with type 2 diabetes in Jiangsu, China. It may help doctors understand how often this liver-related problem occurs and guide future care for people with type 2 diabetes.
This study is looking for people with type 2 diabetes and fatty liver disease to find better ways to track how the disease progresses. They will use special tests (biomarkers) to see if the liver is getting worse over time.
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
This study compares new, non-invasive tests to standard liver biopsy for diagnosing fatty liver disease in people with type 2 diabetes or other signs of metabolic syndrome. It aims to see if these simpler tests can replace biopsies.
Hear when a new MASH - Metabolic Dysfunction-Associated Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.